In an effort to educate the public, media and policymakers about clinical trials and the growing role of clinical research organizations in the drug development process, the Association of Clinical Research Organizations (ACRO) has launched a YouTube channel @ACROHealthChannel.
“Increasingly, the ACRO member companies constitute the global drug development infrastructure,” said John Lewis, ACRO Vice President of Public Affairs. “With a footprint now in 115 countries and responsibility for annually conducting more than 11,000 clinical trials involving two million participants, we have an obligation to engage and educate our various constituencies about issues effecting clinical research. These topics range from ensuring human subject protections to cultivating favorable regulatory and economic environments that promote more efficient drug development.”
The first two videos on ACROHealthChannel feature 2012 ACRO Chairman Jeff McMullen, President and CEO of PharmaNet/i3, discussing the association’s agenda for the year, and Neil McCollough, Vice President of Global Quality and Compliance at Pharmaceutical Product Development, LLC (PPD), discussing issues surrounding bioethics and the globalization of research.
“ACRO strives to be a resource for anyone in the world who is interested in clinical research and drug development,” said Lewis. “We find the ACROHealthChannel, our Twitter feed @acrohealth, and other social media to be effective communications tools to reach a broad audience.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.